Tel：
(86)(21)60969600
Add: Building 28, Lane 588, Tianxiong Road. Shanghai, P. R. China
Shanghai MicroPort EP MedTech Co., Ltd., is pleased to announce that the 4 products which are FireMagic™ radiofrequency ablation catheter, EasyFinder™ fixed or adjustable curved mapping catheter, EasyLoop™ circumferential pulmonary vein mapping catheter and FireMagic® 3D saline infusion radiofrequency ablation catheter received CE certificate on Nov 20th 2013.
FireMagic™ cardiac RF ablation catheter, EasyFinder™ EP diagnostic catheter , EasyLoop™ circular mapping catheter and FireMagic™ 3D irrigated ablation catheter is used in the cardiac electrophysiology diagnostic procedure and radiofrequency ablation. FireMagic™ cardiac RF ablation is mainly used in detailed mapping of electrical cardiac arrhythmia examination which detects different electrophysiological signal. EasyFinder® EP diagnostic catheter is used to detect and extract different signal in pulmonary vein isolation, which is indispensable to the ablation procedure for the treatment of atrial fibrillation.
FireMagic™ 3D irrigated ablation catheter is mainly used in ablation procedure by providing precise locations of the catheter tip in the body and collecting cardiac ECG signal to help physician to effectively maneuver the ablation catheter in the body during the procedure. Currently, the procedure of catheter ablation is gaining wide acceptance in the treatment of atrial fibrillation. The use of FireMagic™ 3D combined with Columbus™ 3D cardiac mapping system provides physicians with a comprehensive solution for the diagnosis and treatment of complex arrhythmias. In addition, Columbus™ with FireMagic™ 3D is the only domestically developed 3D mapping system with the CE certificate.
According to the report from MILLENNIUM RESEARCH GROUP at EUROPEAN MARKETS FOR ELECTROPHYSIOLOGY MAPPING AND ABLATION DEVICES 2012, it is expected that the market for diagnostic catheter and ablation catheter will reach $310 million in 2013. By the end of 2011, the patient population with atrial fibrillation reached 3.3 million in Europe. The procedure volume for atrial fibrillation treatment is expected to reach 36,000 cases in 2013 representing an annual growth rate of 15.1%.
